Setterwalls advises InDex Pharmaceuticals in connection with a conditional reverse merger of Flerie Invest AB

Setterwalls advises InDex Pharmaceuticals in connection with a conditional reverse merger of Flerie Invest AB.

Setterwalls advises InDex Pharmaceuticals Holding AB (publ) (the “Company”) in connection with a conditional reverse merger of Flerie Invest AB. The merger is executed through an issue in kind of new shares in the Company, as a result of which Flerie Invest AB’s shareholders will initially hold approximately 91.9 per cent of the shares in the Company. As a result of the transaction, the Company will change its name to Flerie AB. The transaction is conditional upon, inter alia, transaction-related resolutions at extraordinary general meetings to be held in June 2024 and that the Company receives approval for continued listing of the Company´s share on Nasdaq First North Growth Market. In connection with the completion of the transaction, the intention is to carry out a listing change of the Company´s share from Nasdaq First North Growth Market to Nasdaq Stockholm.